VITAMIN D COMPOUNDS FOR INFLAMMATORY BOWEL DISEASE

点击翻译按钮获取中文摘要

Crohn's disease (CD) and ulcerative colitis (UC) are inflammatory bowel diseases (IBD) of unknown etiology characterized by chronic gastrointestinal (GI) tract inflammation. The key pathological mechanism in IBD may involve a dysregulated immune response to GI tract antigens or infections. Inflammatory Th1 responses characterized by interferon-gamma and tumor necrosis factor-alpha synthesis correlate with IBD, whereas Th2 responses characterized by interleukin-4 and transforming growth factor beta-1 synthesis correlate with protection from IBD. Susceptibility genes contribute to IBD, but inheriting these genes is not sufficient for disease development. Undefined environmental risk factors play a disease-determining role. We hypothesize that insufficient sunlight for vitamin D biosynthesis is an environmental risk factor for IBD. We propose to use the hormonally active vitamin D metabolite, 1,25-dihydroxy vitamin D3 to inhibit IBD development and to treat established IBD in murine models of IBD as a first step in developing a novel therapeutic strategy for this incurable disease. PROPOSED COMMERCIAL APPLICATION: Incurable IBD afflicts two million individuals and costs about $1.2 billion annually to treat. The steroids, immunosuppressants and surgical treatments for IBD symptoms have undesireable side-effects. An FDA-approved short-term treatment (mouse-human IgG1 monoclonal antibody to tumor necrosis factors- alpha) has projected annual sales of $100 million. The commercial potential of a long-term vitamin D-based therapeutic might be greater than $100-150 million.